The results indicated that compound 4 is a hopeful adjuvant drug for hepatocellular carcinoma, and it could become a prospective new promising lead as an HDAC2-targeted anticancer drug; compound 10 has great prospects for being a drug. Here, HDAC2 is linked to hepatocellular carcinoma.